RA Capital Management — Activity

Press

Peter Kolchinsky discussed policy constraints limiting biomedical innovation in a media interview.

Kolchinsky: Policy constraints holding back biomedical innovation

RA Capital Management

racap.comJUN 30, 2026

JUN 30, 2026

Exit

Portfolio company Curevo Vaccine was acquired by Eli Lilly in May 2026.

Curevo Vaccine

Curevo VaccineRA Capital Management

racap.comMAY 2026

MAY 2026

Exit

Portfolio company Ajax Therapeutics was acquired by Eli Lilly in April 2026.

Ajax Therapeutics

Ajax Therapeutics RA Capital Management

racap.comAPR 2026

APR 2026

Exit

Portfolio company Day One Biopharmaceuticals was acquired by Servier in March 2026.

Day One Biopharmaceuticals

Day One Biopharmaceuticals RA Capital Management

racap.comMAR 2026

MAR 2026

Exit

Portfolio company Elektrofi was acquired by Halozyme Therapeutics in November 2025.

Elektrofi

ElektrofiRA Capital Management

racap.comNOV 2025

NOV 2025

Exit

Portfolio company Halda Therapeutics was acquired by Johnson & Johnson in November 2025.

Halda Therapeutics

Halda TherapeuticsRA Capital Management

racap.comNOV 2025

NOV 2025

Exit

Portfolio company Cidara Therapeutics was acquired by Merck & Co. in November 2025.

Cidara Therapeutics

Cidara Therapeutics RA Capital Management

racap.comNOV 2025

NOV 2025

Investment

Provided up to $250M structured loan facility ($100M initial) to ARS Pharma alongside OMERS Life Sciences to fund commercialization of neffy needle-free epinephrine nasal spray.

ARS Pharmaceuticals

ARS PharmaceuticalsRA Capital Management

racap.comSEP 30, 2025 prnewswire.com

SEP 30, 2025

Exit

Portfolio company 89bio was acquired by Roche in September 2025.

89bio

89bio RA Capital Management

racap.comSEP 2025

SEP 2025

Exit

Portfolio company Metsera was acquired by Pfizer in September 2025.

Metsera

Metsera RA Capital Management

racap.comSEP 2025

SEP 2025

Exit

Portfolio company Merus was acquired by Genmab in September 2025.

Merus

MerusRA Capital Management

racap.comSEP 2025

SEP 2025

Exit

Portfolio company HilleVax was acquired by Xoma Royalty in August 2025.

HilleVax

HilleVaxRA Capital Management

racap.comAUG 2025

AUG 2025

Exit

Portfolio company Interius Biotherapeutics was acquired by Kite Pharma (Gilead) in August 2025.

Interius Biotherapeutics

Interius BiotherapeuticsRA Capital Management

racap.comAUG 2025

AUG 2025

New Fund

RA Capital closed its inaugural $120M Planetary Health Fund focused on resource availability, energy innovation, and industrial productivity.

RA Capital Planetary Health Fund ($120M close)

RA Capital Management

racap.comJUL 22, 2025

JUL 22, 2025

RA Capital Management Activity

Peter Kolchinsky discussed policy constraints limiting biomedical innovation in a media interview.

Portfolio company Curevo Vaccine was acquired by Eli Lilly in May 2026.

Portfolio company Ajax Therapeutics was acquired by Eli Lilly in April 2026.

Portfolio company Day One Biopharmaceuticals was acquired by Servier in March 2026.

Portfolio company Elektrofi was acquired by Halozyme Therapeutics in November 2025.

Portfolio company Halda Therapeutics was acquired by Johnson & Johnson in November 2025.

Portfolio company Cidara Therapeutics was acquired by Merck & Co. in November 2025.

Provided up to $250M structured loan facility ($100M initial) to ARS Pharma alongside OMERS Life Sciences to fund commercialization of neffy needle-free epinephrine nasal spray.

Portfolio company 89bio was acquired by Roche in September 2025.

Portfolio company Metsera was acquired by Pfizer in September 2025.

Portfolio company Merus was acquired by Genmab in September 2025.

Portfolio company HilleVax was acquired by Xoma Royalty in August 2025.

Portfolio company Interius Biotherapeutics was acquired by Kite Pharma (Gilead) in August 2025.

RA Capital closed its inaugural $120M Planetary Health Fund focused on resource availability, energy innovation, and industrial productivity.